NO20064788L - Anti-myostatin-anistoffer - Google Patents
Anti-myostatin-anistofferInfo
- Publication number
- NO20064788L NO20064788L NO20064788A NO20064788A NO20064788L NO 20064788 L NO20064788 L NO 20064788L NO 20064788 A NO20064788 A NO 20064788A NO 20064788 A NO20064788 A NO 20064788A NO 20064788 L NO20064788 L NO 20064788L
- Authority
- NO
- Norway
- Prior art keywords
- antibodies
- myostatin
- epitope
- anistoffer
- increasing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
Abstract
Sammendrag 0. nr. P60601579NO00 Det identifiseres en nøytraliserende epitop innen aminosyrene 40-64 av den mature form av human myostatin. Antistoffer som binder denne epitop faller innenfor rammen av oppfinnelsen og kan være murine, kimere eller humaniserte antistoffer, immunokonjugater av antistoffer eller antigenbindende fragmenter derav. Antistoffene ifølge oppfinnelsen er brukbare for å øke muskelmassen, å øke bendensiteten eller for behandling av forskjellige sykdommer i pattedyr.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55545604P | 2004-03-23 | 2004-03-23 | |
US55962104P | 2004-04-05 | 2004-04-05 | |
PCT/US2005/009307 WO2005094446A2 (en) | 2004-03-23 | 2005-03-17 | Anti-myostatin antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064788L true NO20064788L (no) | 2006-12-05 |
Family
ID=35064367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064788A NO20064788L (no) | 2004-03-23 | 2006-10-23 | Anti-myostatin-anistoffer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070178095A1 (no) |
EP (1) | EP1733041B1 (no) |
JP (1) | JP4695133B2 (no) |
KR (1) | KR20060133049A (no) |
AT (1) | ATE557042T1 (no) |
AU (1) | AU2005227896B2 (no) |
BR (1) | BRPI0508716A (no) |
CA (1) | CA2558805C (no) |
EA (1) | EA014112B1 (no) |
ES (1) | ES2384176T3 (no) |
IL (1) | IL177956A (no) |
MX (1) | MXPA06010929A (no) |
NO (1) | NO20064788L (no) |
WO (1) | WO2005094446A2 (no) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ541253A (en) | 2002-12-20 | 2010-03-26 | Amgen Inc | Peptide binding agents which inhibit myostatin |
US7807159B2 (en) * | 2005-04-25 | 2010-10-05 | Amgen Fremont Inc. | Antibodies to myostatin |
WO2007044411A2 (en) * | 2005-10-06 | 2007-04-19 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
MX2008007324A (es) * | 2005-12-06 | 2009-03-04 | Amgen Inc | Usos de antagonistas de miostatina. |
EP4342995A3 (en) | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
JP5058261B2 (ja) * | 2006-09-05 | 2012-10-24 | イーライ リリー アンド カンパニー | 抗ミオスタチン抗体 |
EP2170396B1 (en) | 2007-08-03 | 2016-12-21 | Summit Corporation Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
WO2009041643A1 (ja) | 2007-09-26 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
PE20091163A1 (es) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
EP2313435A4 (en) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
HUP0800448A2 (en) * | 2008-07-21 | 2011-02-28 | Pecsi Tudomanyegyetem | Diagnosis of systemic diseases |
UY32341A (es) | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | Proteínas de unión antígeno novedosas |
FR2943249B1 (fr) * | 2009-03-18 | 2011-08-12 | Genethon | Utilisation de la decorine pour augmenter la masse musculaire |
JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
EP4231014A3 (en) | 2010-11-30 | 2024-03-20 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
PL2780368T3 (pl) | 2011-11-14 | 2018-06-29 | Regeneron Pharmaceuticals, Inc. | Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A |
FR2982860B1 (fr) | 2011-11-18 | 2015-07-10 | Ass Fr Contre Les Myopathies | Utilisation de la fibromoduline et du lumican pour augmenter la masse musculaire |
ES2698606T3 (es) * | 2012-01-20 | 2019-02-05 | Genzyme Corp | Anticuerpos anti-CXCR3 |
WO2013186719A1 (en) * | 2012-06-15 | 2013-12-19 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
RS60318B1 (sr) | 2012-08-01 | 2020-07-31 | Ikaika Therapeutics Llc | Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitela |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
NZ705370A (en) | 2012-08-24 | 2018-06-29 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
MY172863A (en) | 2012-09-13 | 2019-12-13 | Bristol Myers Squibb Co | Fibronectin based scaffold domain proteins that bind to myostatin |
KR102318483B1 (ko) | 2013-04-02 | 2021-10-27 | 추가이 세이야쿠 가부시키가이샤 | Fc영역 개변체 |
WO2014168973A2 (en) | 2013-04-08 | 2014-10-16 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating skeletal muscle stem cells |
AU2014262843B2 (en) | 2013-05-06 | 2017-06-22 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
EP3881859B1 (en) * | 2013-06-11 | 2024-03-06 | President and Fellows of Harvard College | Compositions for increasing neurogenesis and angiogenesis |
TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素a之抗體及其用途 |
WO2015143126A1 (en) | 2014-03-19 | 2015-09-24 | Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof |
CA3005158A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用 |
CA2982810A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
US11359009B2 (en) * | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
EP3949979A1 (en) | 2016-01-06 | 2022-02-09 | President and Fellows of Harvard College | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis |
MX2018008369A (es) | 2016-01-08 | 2019-05-15 | Scholar Rock Inc | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. |
AU2017285764B2 (en) | 2016-06-17 | 2024-05-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
KR20230079499A (ko) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
DK3565592T3 (da) * | 2017-01-06 | 2023-05-01 | Scholar Rock Inc | Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering |
CA3092334A1 (en) | 2018-03-01 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition |
WO2020131910A1 (en) | 2018-12-18 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a |
WO2020132647A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
US20240199728A1 (en) | 2022-09-21 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
EP1333035A3 (en) * | 1993-03-19 | 2004-07-07 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
AU690474B2 (en) * | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
US6103466A (en) * | 1997-07-14 | 2000-08-15 | University Of Liege | Double-muscling in mammals |
US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
GB2333706A (en) * | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
JP4544742B2 (ja) * | 1998-05-06 | 2010-09-15 | メタモーフイクス・インコーポレーテツド | Gdf−8の阻害による糖尿病の処置法 |
US6537781B1 (en) * | 1999-08-10 | 2003-03-25 | Idexx Laboratories, Inc. | Methods and compositions concerning canine interleukin 5 |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
-
2005
- 2005-03-17 AU AU2005227896A patent/AU2005227896B2/en not_active Ceased
- 2005-03-17 WO PCT/US2005/009307 patent/WO2005094446A2/en active Application Filing
- 2005-03-17 EP EP05734951A patent/EP1733041B1/en not_active Revoked
- 2005-03-17 EA EA200601752A patent/EA014112B1/ru not_active IP Right Cessation
- 2005-03-17 KR KR1020067021903A patent/KR20060133049A/ko not_active Application Discontinuation
- 2005-03-17 JP JP2007505055A patent/JP4695133B2/ja not_active Expired - Fee Related
- 2005-03-17 CA CA2558805A patent/CA2558805C/en not_active Expired - Fee Related
- 2005-03-17 ES ES05734951T patent/ES2384176T3/es active Active
- 2005-03-17 BR BRPI0508716-3A patent/BRPI0508716A/pt not_active IP Right Cessation
- 2005-03-17 AT AT05734951T patent/ATE557042T1/de active
- 2005-03-17 US US10/593,810 patent/US20070178095A1/en not_active Abandoned
- 2005-03-17 MX MXPA06010929A patent/MXPA06010929A/es active IP Right Grant
-
2006
- 2006-09-07 IL IL177956A patent/IL177956A/en not_active IP Right Cessation
- 2006-10-23 NO NO20064788A patent/NO20064788L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200601752A1 (ru) | 2007-02-27 |
JP2007530551A (ja) | 2007-11-01 |
WO2005094446A3 (en) | 2005-12-22 |
EP1733041B1 (en) | 2012-05-09 |
CA2558805A1 (en) | 2005-10-13 |
KR20060133049A (ko) | 2006-12-22 |
JP4695133B2 (ja) | 2011-06-08 |
IL177956A (en) | 2010-11-30 |
EP1733041A2 (en) | 2006-12-20 |
BRPI0508716A (pt) | 2007-08-07 |
EA014112B1 (ru) | 2010-10-29 |
AU2005227896A1 (en) | 2005-10-13 |
ATE557042T1 (de) | 2012-05-15 |
MXPA06010929A (es) | 2007-01-16 |
IL177956A0 (en) | 2006-12-31 |
US20070178095A1 (en) | 2007-08-02 |
AU2005227896B2 (en) | 2008-11-13 |
EP1733041A4 (en) | 2009-01-28 |
WO2005094446A2 (en) | 2005-10-13 |
CA2558805C (en) | 2011-09-27 |
ES2384176T3 (es) | 2012-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200601752A1 (ru) | Антимиостатиновые антитела | |
WO2007044411A3 (en) | Anti-myostatin antibodies | |
UA92504C2 (en) | Anti-myostatin monoclonal antibody | |
NL301196I2 (nl) | inebilizumab | |
HRP20181459T1 (hr) | Humanizirani antagonisti anti-beta7 i njihove uporabe | |
WO2006138729A3 (en) | Receptor antagonists for treatment of metastatic bone cancer | |
CY1113224T1 (el) | Νεο αντισωμα αντι-ρlgf | |
MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
TN2009000383A1 (en) | Anti - sclerostin antibodies | |
EA200702053A1 (ru) | Антитела против cd38 для лечения множественной миеломы | |
DK3284753T3 (da) | Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose | |
IL187594A0 (en) | Humanized anti-cd40 antibodies and their methods of use | |
PH12020551037A1 (en) | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods | |
WO2009135861A3 (en) | Humanized antibodies against human interferon-alpha | |
MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
CR20220047A (es) | Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados | |
WO2003073982A3 (en) | Anti-interleukin-1 beta analogs | |
EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
WO2007101021A3 (en) | Humanized anti-ghrelin antibodies | |
ZA202205813B (en) | Trpv1 epitopes and antibodies | |
WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease | |
TW200740845A (en) | Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue | |
CY1115979T1 (el) | Αντισωματα κατα της μυοστατινης | |
CY1116887T1 (el) | Anti-cd19 αντισωματα και χρησεις στην ογκολογια |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |